ANI Pharmaceuticals Profile

56.44
USD 1.44  2.62%
96%
80%

Payment of 991 shares by Arthur Przybyl of ANI Pharmaceuticals subject to Rule 16b-3

ANI Pharmaceuticals insider trading alert for payment of common stock by Arthur Przybyl, President and CEO, on October 10, 2018. This event was filed by Ani Pharmaceuticals Inc with SEC on 2017-05-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

ANI Pharmaceuticals Summary

ANI Pharmaceuticals (ANIP) is traded on BATS Exchange in USA. It is located in Minnesota U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 663.46 M. ANI Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 11.82 M outstanding shares of which 1.06 M shares are presently shorted by private and institutional investors with about 13.33 trading days to cover. ANI Pharmaceutica currently holds about 54.99 M in cash with 6.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.65.
Check ANI Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

ANI Pharmaceuticals Target Price Odds Analysis

Odds Below 56.44HorizonTargetOdds Above 56.44
90.15%30 days 56.44 9.62%
Based on normal probability distribution, the odds of ANI Pharmaceuticals to move above current price in 30 days from now is about 9.62% (This ANI Pharmaceuticals probability density function shows the probability of ANI Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

ANI Pharmaceuticals Top Holders

ANI Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

ANI Pharmaceuticals Key Fundamentals

ANI Pharmaceuticals Against Markets

ANI Pharmaceuticals Current Ratings

ANI Pharmaceuticals 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
2 
Chance of
Financial Distress (0 to 100%)
37 
Equity ratings for ANI Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 173 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
ANI Pharmaceuticals SEC Filings
ANI Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameANI Pharmaceuticals
CEO and President and DirectorArthur PrzybylView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationMinnesota U.S.A
Business Address210 Main Street West
ExchangeBATS Exchange
CIK Number0001023024
CUSIP09065V203
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.anipharmaceuticals.com
Phone218 634 3500
Related EntityBPA
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestSeptember 14, 2018

ANI Pharmaceuticals Directors

ANI Pharmaceuticals Corporate Directors

David Nash Independent Director
Daniel Raynor Director
Thomas Haughey Independent Director
Check also Trending Equities. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com